Literature DB >> 20856733

Longitudinal patterns of chemotherapy use in metastatic colorectal cancer.

S Yousuf Zafar1, Jennifer E Marcello, Jane L Wheeler, Krista L Rowe, Michael A Morse, James E Herndon, Amy P Abernethy.   

Abstract

Multiple agents and combination therapies available to patients with advanced colorectal cancer have significantly improved survival and provided an opportunity for individualization of care, allowing clinicians and patients to prioritize risks and benefits of comparable regimens.

Entities:  

Year:  2009        PMID： 20856733      PMCID： PMC2790671          DOI： 10.1200/JOP.091010

Source DB:  PubMed          Journal:  J Oncol Pract        ISSN： 1554-7477            Impact factor:   3.840


  17 in total

1.  Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR.

Authors:  F Maindrault-Goebel; C Louvet; T André; E Carola; J P Lotz; J L Molitor; M L Garcia; V Gilles-Amar; V Izrael; M Krulik; A de Gramont
Journal:  Eur J Cancer       Date:  1999-09       Impact factor: 9.162

Review 2.  The continuum of care: a paradigm for the management of metastatic colorectal cancer.

Authors:  Richard M Goldberg; Mace L Rothenberg; Eric Van Cutsem; Al B Benson; Charles D Blanke; Robert B Diasio; Axel Grothey; Heinz-Josef Lenz; Neal J Meropol; Ramesh K Ramanathan; Carlos H Roberto Becerra; Rita Wickham; Delma Armstrong; Carol Viele
Journal:  Oncologist       Date:  2007-01

3.  Analysis of treatment practices for elderly cancer patients in Ontario, Canada.

Authors:  Carol Townsley; Gregory R Pond; Brenda Peloza; Joanne Kok; Kendra Naidoo; Darlene Dale; Carole Herbert; Eric Holowaty; Sharon Straus; Lillian L Siu
Journal:  J Clin Oncol       Date:  2005-06-01       Impact factor: 44.544

4.  Age and adjuvant chemotherapy use after surgery for stage III colon cancer.

Authors:  D Schrag; L D Cramer; P B Bach; C B Begg
Journal:  J Natl Cancer Inst       Date:  2001-06-06       Impact factor: 13.506

5.  Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older.

Authors:  R A Popescu; A Norman; P J Ross; B Parikh; D Cunningham
Journal:  J Clin Oncol       Date:  1999-08       Impact factor: 44.544

6.  Who gets adjuvant treatment for stage II and III rectal cancer? Insight from surveillance, epidemiology, and end results--Medicare.

Authors:  D Schrag; S E Gelfand; P B Bach; J Guillem; B D Minsky; C B Begg
Journal:  J Clin Oncol       Date:  2001-09-01       Impact factor: 44.544

7.  FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.

Authors:  Christophe Tournigand; Thierry André; Emmanuel Achille; Gérard Lledo; Michel Flesh; Dominique Mery-Mignard; Emmanuel Quinaux; Corinne Couteau; Marc Buyse; Gérard Ganem; Bruno Landi; Philippe Colin; Christophe Louvet; Aimery de Gramont
Journal:  J Clin Oncol       Date:  2003-12-02       Impact factor: 44.544

8.  A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.

Authors:  Richard M Goldberg; Daniel J Sargent; Roscoe F Morton; Charles S Fuchs; Ramesh K Ramanathan; Stephen K Williamson; Brian P Findlay; Henry C Pitot; Steven R Alberts
Journal:  J Clin Oncol       Date:  2003-12-09       Impact factor: 44.544

9.  Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

Authors:  Leonard B Saltz; Stephen Clarke; Eduardo Díaz-Rubio; Werner Scheithauer; Arie Figer; Ralph Wong; Sheryl Koski; Mikhail Lichinitser; Tsai-Shen Yang; Fernando Rivera; Felix Couture; Florin Sirzén; Jim Cassidy
Journal:  J Clin Oncol       Date:  2008-04-20       Impact factor: 44.544

10.  Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803.

Authors:  Leonard B Saltz; Donna Niedzwiecki; Donna Hollis; Richard M Goldberg; Alexander Hantel; James P Thomas; Anthony L A Fields; Robert J Mayer
Journal:  J Clin Oncol       Date:  2007-08-10       Impact factor: 44.544
View more
  12 in total

Review 1.  Evolvement of the treatment paradigm for metastatic colon cancer. From chemotherapy to targeted therapy.

Authors:  Santiago Aparo; Sanjay Goel
Journal:  Crit Rev Oncol Hematol       Date:  2011-09-23       Impact factor: 6.312

2.  Commentary: practice patterns and potential impact on quality measures for a practicing physician.

Authors:  Cathy Eng; Scott Kopetz
Journal:  J Oncol Pract       Date:  2009-09       Impact factor: 3.840

3.  Cost-effectiveness analysis of selective first-line use of biologics for unresectable RAS wild-type left-sided metastatic colorectal cancer.

Authors:  W W L Wong; M Zargar; S R Berry; Y J Ko; M Riesco-Martínez; K K W Chan
Journal:  Curr Oncol       Date:  2019-10-01       Impact factor: 3.677

4.  A retrospective observational study to estimate the attrition of patients across lines of systemic treatment for metastatic colorectal cancer in Canada.

Authors:  H Kennecke; S Berry; J Maroun; P Kavan; N Aucoin; F Couture; M Poulin-Costello; B Gillesby
Journal:  Curr Oncol       Date:  2019-12-01       Impact factor: 3.677

5.  Patterns of Chemotherapy Use in a U.S.-Based Cohort of Patients with Metastatic Pancreatic Cancer.

Authors:  Thomas A Abrams; Gary Meyer; Jeffrey A Meyerhardt; Brian M Wolpin; Deborah Schrag; Charles S Fuchs
Journal:  Oncologist       Date:  2017-05-05

6.  Neuropathic Symptoms and Their Risk Factors in Medical Oncology Outpatients With Colorectal vs. Breast, Lung, or Prostate Cancer: Results From a Prospective Multicenter Study.

Authors:  Mark A Lewis; Fengmin Zhao; Desiree Jones; Charles L Loprinzi; Joanna Brell; Matthias Weiss; Michael J Fisch
Journal:  J Pain Symptom Manage       Date:  2015-01-14       Impact factor: 3.612

7.  Oncologists' response to new data regarding the use of epidermal growth factor receptor inhibitors in colorectal cancer.

Authors:  Efrat Dotan; Tianyu Li; Michael J Hall; Neal J Meropol; J Robert Beck; Yu-Ning Wong
Journal:  J Oncol Pract       Date:  2014-07-22       Impact factor: 3.840

8.  Unsupported off-label chemotherapy in metastatic colon cancer.

Authors:  Jonas A de Souza; Blase Polite; Monica Perkins; Neal J Meropol; Mark J Ratain; Lee N Newcomer; G Caleb Alexander
Journal:  BMC Health Serv Res       Date:  2012-12-29       Impact factor: 2.655

9.  Tolerability of Capecitabine Monotherapy in Metastatic Colorectal Cancer: A Real-World Study.

Authors:  Laura W Leicher; Jacques C de Graaf; Wilko Coers; Metin Tascilar; Jan Willem B de Groot
Journal:  Drugs R D       Date:  2017-03

10.  Patterns of Biologics Use Across Treatment Lines in Elderly (Age >65) Medicare Patients With Metastatic Colon Cancer.

Authors:  Kaloyan A Bikov; C Daniel Mullins; Anna Hung; Brian Seal; Eberechukwu Onukwugha; Nader Hanna
Journal:  Oncologist       Date:  2016-04-28       Impact factor: 5.837
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.